Followers | 88 |
Posts | 8196 |
Boards Moderated | 0 |
Alias Born | 06/17/2013 |
Sunday, September 16, 2018 10:47:24 AM
Since May 1st of this year :
(working backwards from the latest PR)
NEWS : 9/4/18
https://ih.advfn.com/p.php?pid=nmona&article=78186786
Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access
of its StemVacs Product for American Cancer Patients
Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA under President Donald Trump's
Right to Try Law
fety and signals of efficacy obtained from the current Phase I clinical trial, support us to expand the use of StemVacs under President Trump's recently passed Right to Try Law."
NEWS : 8/22/18
https://ih.advfn.com/p.php?pid=nmona&article=78119448
Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players
Company to Advance NeuroStilbene Product for High-Performance Athletes
Susceptible to Head Injuries
NEWS : 8/13/18
https://ih.advfn.com/p.php?pid=nmona&article=78060284
Therapeutic Solutions International Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene
Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline
NEWS : 8/6/18
https://ih.advfn.com/p.php?pid=nmona&article=78013140
Therapeutic Solutions International Develops Microemulsion Formulation of
Alpha Lipoic Acid for Intranasal Delivery
Company Expands Product Pipeline in Neurodegenerative Arena
NEWS : 7/23/18
https://ih.advfn.com/p.php?pid=nmona&article=77913150
Therapeutic Solutions International Recruits Internationally Recognized Cancer Immunotherapy Pioneer Dr. Francesco Marincola to Accelerate StemVacs and NanoStilbene Clinical Development
Company Focuses on Non-Toxic Therapies Using Immune System
to Selectively Kill Cancer Cells through Immunotherapy
NEWS : 7/16/18
https://ih.advfn.com/p.php?pid=nmona&article=77868683
Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for
Rapid Access to Blood-Brain Barrier
Company Expands its Pterostilbene Based Portfolio into Brain Cancers
Oceanside, CA -- July 16, 2018 -- Investorshub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the release of NeuroStilbene, a proprietary nano-formulation of pterostilbene formulated for intranasal delivery.
NEWS : 7/9/18
https://ih.advfn.com/p.php?pid=nmona&article=77825316
Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board
Pioneer of Functional Medicine Teams Up with Clinical Stage Biotechnology Company in Commercialization of Non-Toxic Immunotherapy
NEWS : 7/2/18
https://ih.advfn.com/p.php?pid=nmona&article=77784227
Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™
Early Clinical Trial Data Supports Enhanced Biodistribution of NanoStilbene™ Compared to Standard Pterostilbene When Orally Administered
NEWS : 6/25/18
https://ih.advfn.com/p.php?pid=nmona&article=77734511
Therapeutic Solutions International Releases "IsoStilbene" Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells . IsoStilbene to be Included in Pan American Cancer Treatment Center Protocols
NEWS : 6/18/18
https://ih.advfn.com/p.php?pid=nmona&article=77684969
Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer
Oceanside, CA -- June 18, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as Chief Medical Officer of their future planned cancer clinic.
NEWS : 6/11/18
ih.advfn.com/p.php?pid=nmona&article=77635806
Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" into StemVacs Dendritic Cell Platform
OCEANSIDE, CA -- June 11, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today initiation of efforts to combine its existing CTCFL "universal cancer antigen", labeled as BRS-001, with its clinical stage StemVacs Dendritic Cell Platform.
BORIS Info:
http://stemvacs.com/?page_id=145
NEWS : 6/6/18
http://ih.advfn.com/p.php?pid=nmona&article=77606645
Therapeutic Solutions International Announces Licensing of Additional Technologies to
Pan American Cancer Treatment Center
Patent Title: Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants : Cancer Metabolic DeTox
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-targeting-tumor-microenvironment-through-nutraceutical-otc-pink-tsoi-2215015.htm
Patent Title: Methods of Re-Activating Dormant Memory Cells with Anticancer Activity : MemoryMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-methods-re-activating-dormant-memory-cells-with-otc-pink-tsoi-2220094.htm
Patent Title: Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization : StemVacs
http://www.marketwired.com/press-release/therapeutic-solutions-international-announces-filing-new-immunotherapy-patent-exclusive-otc-pink-tsoi-2208787.htm
Patent Title:Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof : LymphoBoost
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-augmentation-anti-tumor-immunity-mifepristone-otc-pink-tsoi-2217703.htm
Patent Title: Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients : innaMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-blood-derived-innate-immune-system-stimulator-otc-pink-tsoi-2216672.htm
Pan Am Cancer Treatment Center
Telephone: (619) 735-9581
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010
www.cancerimmunotherapy.mx
info@cancerimmunotherapy.mx
Pan Am Cancer Treatment Center Intoductory video :
NEWS : 5/31/18
http://ih.advfn.com/p.php?pid=nmona&article=77561606
Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Newly Passed Right to Try Law
NEWS : 5/21/18
http://ih.advfn.com/p.php?pid=nmona&article=77477228
Therapeutic Solutions International Releases "DermalStilbene" a Topical Formulation of Pterostilbene
NEWS : 5/15/18
http://ih.advfn.com/p.php?pid=nmona&article=77431704
Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant Nanostilbene
NEWS : 5/9/18
http://ih.advfn.com/p.php?pid=nmona&article=77382606
Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board
Company to Iniate Investigational Cardiovascular Study with Dr. Azimi and Nanostilbene
NEWS : 5/1/18
http://ih.advfn.com/p.php?pid=nmona&article=77309980
Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment
Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene
Link to Pan Am Cancer Treatment Centers website :
http://cancerimmunotherapy.mx/web/
Link to TSOI Patent covering NanoStilbene :
https://patents.google.com/patent/US9682047B2/en
StemVacs is also the subject of a filed Investigational New Drug Application (IND #17448) with the U.S. FDA. The IND seeks to establish safety and immune response of cancer, targeting a new personalized dendritic cell vaccine.
StemVacs Website :
http://stemvacs.com
Link to TSOI StemVacs PR :
http://www.marketwired.com/press-release/-2209423.htm
Link to BORIS/StemVacs patent application :
https://patents.google.com/patent/US20170143812
Recent TSOI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:44:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:44:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 06:14:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 07:42:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 07:38:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:44:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:39:55 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/31/2024 08:51:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 04:47:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:46:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:44:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/30/2024 06:46:26 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 04:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 10:03:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 07:44:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 05:39:49 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM